Susquehanna International Group
VRDN icon

Susquehanna International Group’s Viridian Therapeutics VRDN Stock Holding History

Susquehanna International Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.56M Buy
233,300
+216,900
+1,323% +$6.44M ﹤0.01% 4394
2025
Q4 		$510K Sell
16,400
-31,200
-66% -$856K ﹤0.01% 8738
2025
Q3 		$1.03M Sell
47,600
-184,100
-79% -$3.32M ﹤0.01% 7299
2025
Q2 		$3.24M Buy
231,700
+221,600
+2,194% +$3.01M ﹤0.01% 4817
2025
Q1 		$136K Sell
10,100
-201,000
-95% -$3.42M ﹤0.01% 11303
2024
Q4 		$4.05M Buy
211,100
+111,600
+112% +$2.43M ﹤0.01% 3929
2024
Q3 		$2.26M Buy
99,500
+76,100
+325% +$1.24M ﹤0.01% 5034
2024
Q2 		$304K Buy
23,400
+2,200
+10% +$30.5K ﹤0.01% 9410
2024
Q1 		$371K Buy
21,200
+7,600
+56% +$147K ﹤0.01% 9207
2023
Q4 		$296K Buy
+13,600
New +$215K ﹤0.01% 9869
2023
Q3 		– Sell
-244,500
Closed -$5.82M – 13086
2023
Q2 		$5.82M Buy
244,500
+228,900
+1,467% +$5.87M ﹤0.01% 3287
2023
Q1 		$397K Buy
+15,600
New +$500K ﹤0.01% 9113
2022
Q4 		– Sell
-27,300
Closed -$560K – 13782
2022
Q3 		$560K Buy
+27,300
New +$491K ﹤0.01% 8191

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's VRDN Position: Q1 2026 in Review

Susquehanna International Group reduced its Viridian Therapeutics (VRDN) stake by 53% in Q1 2026, selling an estimated $1.85M and leaving 54,277 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #7737.

Susquehanna International Group first reported a position in VRDN in Q1 2015 and has held it in 22 quarters since. The position peaked at $5M in Q2 2023. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Susquehanna International Group held 54,277 shares of Viridian Therapeutics worth $1.06M as of Q1 2026.
  • Susquehanna International Group sold 62,247 Viridian Therapeutics shares in Q1 2026, an estimated $1.85M.
  • Viridian Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7737 holding.
  • Susquehanna International Group first reported a position in Viridian Therapeutics in Q1 2015 and has held it in 22 quarters since.
  • Susquehanna International Group's Viridian Therapeutics position peaked at $5M in Q2 2023.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.